Insights

Strategic Partnerships Melinta has recently partnered with Mundipharma International for the US distribution of rezafungin and collaborated with Venatorx Pharmaceuticals for the commercialization of cefepime-taniborbactam, highlighting opportunities to co-market or expand pharmaceutical collaborations in infectious diseases.

Product Launches The commercial launch of Kimyrsa indicates ongoing product development efforts, suggesting sales opportunities for healthcare providers and institutions adopting new antibiotics for acute and life-threatening infections.

Recent Acquisitions Acquisition by CorMedix for 300M underscores Melinta's growth and valuation, presenting prospects to target the expanded infectious disease portfolio and leverage their increased market presence for sales expansion.

Leadership Expansion New executive hires in technical operations and medical affairs demonstrate a focus on innovation and regulatory excellence, which can be leveraged to position new or existing therapies for better market acceptance.

Financial Opportunity With a revenue range of 25 to 50 million and substantial funding of 90 million, there is significant potential to penetrate hospitals and clinics that are investing in advanced infectious disease treatments and innovative biotech solutions.

Similar companies to Melinta Therapeutics

Melinta Therapeutics Tech Stack

Melinta Therapeutics uses 8 technology products and services including SiteCatalyst, GDPR, RSS, and more. Explore Melinta Therapeutics's tech stack below.

  • SiteCatalyst
    Analytics
  • GDPR
    Certificates
  • RSS
    Content Management System
  • JD Edwards
    Enterprise
  • Veeva Systems
    IT Infrastructure & Operations Management
  • Backbone.js
    Javascript Frameworks
  • Element UI
    Javascript Frameworks
  • SAP Concur
    Travel And Expense Management

Media & News

Melinta Therapeutics's Email Address Formats

Melinta Therapeutics uses at least 1 format(s):
Melinta Therapeutics Email FormatsExamplePercentage
FLast@melinta.comJDoe@melinta.com
99%
Last@melinta.comDoe@melinta.com
1%

Frequently Asked Questions

Where is Melinta Therapeutics's headquarters located?

Minus sign iconPlus sign icon
Melinta Therapeutics's main headquarters is located at 389 Interpace Parkway Suite 450 Parsippany, New Jersey 07054 United States. The company has employees across 3 continents, including North AmericaEuropeSouth America.

What is Melinta Therapeutics's phone number?

Minus sign iconPlus sign icon
You can contact Melinta Therapeutics's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Melinta Therapeutics's stock symbol?

Minus sign iconPlus sign icon
Melinta Therapeutics is a publicly traded company; the company's stock symbol is MLNTQ.

What is Melinta Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Melinta Therapeutics's official website is melinta.com and has social profiles on LinkedInCrunchbase.

What is Melinta Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
Melinta Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Melinta Therapeutics have currently?

Minus sign iconPlus sign icon
As of May 2026, Melinta Therapeutics has approximately 75 employees across 3 continents, including North AmericaEuropeSouth America. Key team members include Chief Scientific Officer: E. D.Vice President Of Drug Development: D. G.Vp Medical Affairs: M. R.. Explore Melinta Therapeutics's employee directory with LeadIQ.

What industry does Melinta Therapeutics belong to?

Minus sign iconPlus sign icon
Melinta Therapeutics operates in the Biotechnology Research industry.

What technology does Melinta Therapeutics use?

Minus sign iconPlus sign icon
Melinta Therapeutics's tech stack includes SiteCatalystGDPRRSSJD EdwardsVeeva SystemsBackbone.jsElement UISAP Concur.

What is Melinta Therapeutics's email format?

Minus sign iconPlus sign icon
Melinta Therapeutics's email format typically follows the pattern of FLast@melinta.com. Find more Melinta Therapeutics email formats with LeadIQ.

Melinta Therapeutics

Biotechnology ResearchNew Jersey, United States51-200 Employees

High touch and big impact are trademarks of Melinta. We are nimble and agile without sacrificing our dedication to adding value everywhere we go.

You see, the people of Melinta are believers. Woven into the fiber of our culture is tenacity, brilliance, resilience, excellence and courage. Nothing can weaken our resolve. We take each responsibility seriously, because when we make a move, it matters.

Watch us as we grow. We are the company of the moment and the enterprise of the future. We’re unparalleled in our ability to meet the unmet needs of our patients, and we do so collaboratively. Because we believe the most diverse teams produce the most meaningful impact.

We can’t wait to make legendary strides. Every step counts.

Section iconCompany Overview

Headquarters
389 Interpace Parkway Suite 450 Parsippany, New Jersey 07054 United States
Phone number
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
MLNTQ
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
51-200

Section iconFunding & Financials

  • $25M$50M

    Melinta Therapeutics's revenue is estimated to be in the range of $25M$50M

Section iconFunding & Financials

  • $25M$50M

    Melinta Therapeutics's revenue is estimated to be in the range of $25M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.